Abbott is taking two of its continuous glucose monitoring (CGM) technologies over the counter. The Abbott Park, IL-based company said it won nods from FDA for the Lingo and Libre Rio, based on its ...

ABBOTT PARK, Ill., June 10, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) ...

Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.

While the Lingo CGM is designed for general consumers looking to improve their health, the Libre Rio OTC CGM system is intended for adults with type 2 diabetes who do not use insulin. The Food and ...

(RTTNews) - Abbott Laboratories (ABT) Monday announced FDA clearance for two new over-the-counter continuous glucose monitoring systems - Lingo and Libre Rio. Abbott said, these two systems are based ...

(Reuters) -Abbott Laboratories said on Monday the U.S. health regulator had cleared the company's two new over-the-counter glucose monitoring devices, expanding its presence in a fast-growing, ...

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for incorrect high glucose readings. After parts of her large intestine died and ...

Abbott’s diabetes division thought joining the over-the-counter market looked so nice they did it twice. The company has collected FDA clearances for two separate continuous glucose monitoring systems ...

Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This ...

Global healthcare company, Abbott, announced that its continuous glucose monitoring system Lingo can now be purchased in the U.S. without a prescription. Lingo contains a biosensor and mobile app that ...